Multiple automated minibioreactor system for multifunctional screening in biotechnology

Fontova, A.; Soley, A.; Gálvez, J.; Sarró, E.; Lecina, Martí; Rosell, Jan; Riu, Pere J.; Cairó, Jordi J.; Gòdia, Francesc; Bragós, Ramon

doi:10.1109/iembs.2006.4397480

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in other bioreactors, it is possible to control culture parameters such as pH, DOT, temperature, etc. The versatile size offered by such systems range from 1 mL up to 2,000 L at industrial scale (Fontova et al 2006). These types of bioreactors have been used to promote the cultivation of various cells including bacteria, yeast, plant cells (Girard et al 2006), insect cells (Kadwell and Hardwicke 2007), and various mammalian cells (Hahnel et al 2011;Yuk et al 2011).…”

Section: Disposable Bioreactorsmentioning

confidence: 99%

Recent advances in technology supporting biopharmaceutical production from mammalian cells

Butler

Meneses‐Acosta

2012

Appl Microbiol Biotechnol

177

View full text Add to dashboard Cite

The demand for production of glycoproteins from mammalian cell culture continues with an increased number of approvals as biopharmaceuticals for the treatment of unmet medical needs. This is particularly the case for humanized monoclonal antibodies which are the largest and fastest growing class of therapeutic pharmaceuticals. This demand has fostered efforts to improve the efficiency of production as well as to address the quality of the final product. Chinese hamster ovary cells are the predominant hosts for stable transfection and high efficiency production on a large scale. Specific productivity of recombinant glycoproteins from these cells can be expected to be above 50 pg/cell/day giving rise to culture systems with titers of around 5 g/L if appropriate fed-batch systems are employed. Cell engineering can delay the onset of programmed cell death to ensure prolonged maintenance of productive viable cells. The clinical efficacy and quality of the final product can be improved by strategic metabolic engineering. The best example of this is the targeted production of afucosylated antibodies with enhanced antibody-dependent cell cytotoxicity, an important function for use in cancer therapies. The development of culture media from non-animal sources continues and is important to ensure products of consistent quality and without the potential danger of contamination. Process efficiencies may also be improved by employing disposable bioreactors with the associated minimization of downtime. Finally, advances in downstream processing are needed to handle the increased supply of product from the bioreactor but maintaining the high purity demanded of these biopharmaceuticals.

show abstract

Section: Disposable Bioreactorsmentioning

confidence: 99%

Recent advances in technology supporting biopharmaceutical production from mammalian cells

Butler

Meneses‐Acosta

2012

Appl Microbiol Biotechnol

177

View full text Add to dashboard Cite

show abstract

“…A number of parallel miniaturized MBR systems have entered the market in recent years , including HexaScreen's ® multiple mini‐bioreactor system , Pall's micro24 , m2p Labs' BioLector ® , the SimCell microbioreactor and TAP Biosystem's ambr ® microbioreactor . These systems range in working volume from a few hundred microliters to 15 mL, and, due to the small volumes as compared to shake flasks and traditional benchtop BRs, allow for the parallel growth and comparison of a number of different cell lines and growth conditions.…”

Section: Scale‐up Selection Methodsmentioning

confidence: 99%

High‐throughput screening and selection of mammalian cells for enhanced protein production

Priola

Calzadilla

Baumann

et al. 2016

Biotechnology Journal

View full text Add to dashboard Cite

The production of recombinant proteins for biotherapeutic use is a multibillion dollar industry, which has seen continual growth in recent years. In order to produce the best protein with minimal cost and time, selection methods are utilized during the cell line development process in order to select for the most desirable clonal cell line from a heterogeneous transfectant pool. Today, there is a vast array of potential selection methods available, which vary in cost, complexity and efficacy. This review aims to highlight cell line selection methods that exist for the isolation of high-producing clones, and also reviews techniques that can be used to predict, at a small scale, the performance of clones at large, industrially-relevant scales.

show abstract

“…The term 'bioreactor' can be used to identify several devices for different purposes in the field of either medicine or life sciences: various examples in the literature range from microwell plates (for drug tests on cell culture) [53] to biological mass production in industrial plants.…”

Section: Bioreactors For Tehv: Definition and Functionsmentioning

confidence: 99%

Cells, scaffolds and bioreactors for tissue-engineered heart valves: a journey from basic concepts to contemporary developmental innovations☆

Gandaglia

Bagno

Naso

et al. 2011

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

The development of viable and functional tissue-engineered heart valves (TEHVs) is a challenge that, for almost two decades, the scientific community has been committed to face to create life-lasting prosthetic devices for treating heart valve diseases. One of the main drawbacks of tissue-based commercial substitutes, xenografts and homografts, is their lack of viability, and hence failure to grow, repair, and remodel. In adults, the average bioprostheses life span is around 13 years, followed by structural valve degeneration, such as calcification; in pediatric, mechanical valves are commonly used instead of biological substitutes, as in young patients, the mobilization of calcium, due to bone remodeling, accelerates the calcification process. Moreover, neither mechanical nor bioprostheses are able to follow children's body growth. Cell seeding and repopulation of acellular heart valve scaffolds, biological and polymeric, appears as a promising way to create a living valve. Biomechanical stimuli have significant impact on cell behavior including in vitro differentiation, and physiological hemodynamic conditioning has been found to promote new tissue development. These concepts have led scientists to design bioreactors to mimic the in vivo environment of heart valves. Many different types of somatic and stem cells have been tested for colonizing both the surface and the core of the valve matrix but controversial results have been achieved so far.

show abstract

Multiple automated minibioreactor system for multifunctional screening in biotechnology

Cited by 3 publications

References 0 publications

Recent advances in technology supporting biopharmaceutical production from mammalian cells

Recent advances in technology supporting biopharmaceutical production from mammalian cells

High‐throughput screening and selection of mammalian cells for enhanced protein production

Cells, scaffolds and bioreactors for tissue-engineered heart valves: a journey from basic concepts to contemporary developmental innovations☆

Contact Info

Product

Resources

About